Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trial designs using real‐world data: The changing landscape of the regulatory approval process
Elodie Baumfeld Andre, Robert F. Reynolds, Patrick Caubel, et al.
Pharmacoepidemiology and Drug Safety (2019) Vol. 29, Iss. 10, pp. 1201-1212
Open Access | Times Cited: 197

Showing 1-25 of 197 citing articles:

The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License Applications
Christina A. Purpura, Elizabeth M. Garry, Nicholaas Honig, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 111, Iss. 1, pp. 135-144
Open Access | Times Cited: 111
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders
Borwin Bandelow, Christer Allgulander, David S. Baldwin, et al.
The World Journal of Biological Psychiatry (2022) Vol. 24, Iss. 2, pp. 79-117
Closed Access | Times Cited: 72
Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World
Leah Burns, Nadege Le Roux, Robert Kalesnik-Orszulak, et al.
Clinical Therapeutics (2022) Vol. 44, Iss. 3, pp. 420-437
Open Access | Times Cited: 70
Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design
Simon Dagenais, Leo Russo, Ann Madsen, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 111, Iss. 1, pp. 77-89
Open Access | Times Cited: 89
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
John G. Rizk, Donald N. Forthal, Kamyar Kalantar‐Zadeh, et al.
Drug Discovery Today (2020) Vol. 26, Iss. 2, pp. 593-603
Open Access | Times Cited: 77
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Aaron C. Tan, Stephen Bagley, Patrick Y. Wen, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 7, pp. e002459-e002459
Open Access | Times Cited: 63
Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making
Elisabeth Bakker, Kelly Plueschke, Carla J. Jonker, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 1, pp. 135-151
Open Access | Times Cited: 44
A causal roadmap for generating high-quality real-world evidence
Lauren Eyler Dang, Susan Gruber, Hana Lee, et al.
Journal of Clinical and Translational Science (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 28
Single-arm clinical trials: design, ethics, principles
Minyan Wang, Huan Ma, Yun Shi, et al.
BMJ Supportive & Palliative Care (2024), pp. spcare-004984
Open Access | Times Cited: 8
Real-world data: bridging the gap between clinical trials and practice
Brooke E. Wilson, Christopher M. Booth
EClinicalMedicine (2024) Vol. 78, pp. 102915-102915
Closed Access | Times Cited: 8
Disparities in access to anti-HER2 therapies in neoadjuvant chemotherapy: A prognostic analysis based on real-world data comparing Brazil’s public and private healthcare systems
Marcelo Antonini, André Mattar, Denise Joffily Pereira da Costa Pinheiro, et al.
The Breast (2025) Vol. 80, pp. 104417-104417
Open Access | Times Cited: 1
The use of external controls: To what extent can it currently be recommended?
Hans Ulrich Burger, Christoph Gerlinger, Chris Harbron, et al.
Pharmaceutical Statistics (2021) Vol. 20, Iss. 6, pp. 1002-1016
Open Access | Times Cited: 53
Real World Evidence in Medical Cannabis Research
R. Banerjee, Simon Erridge, Oliver Salazar, et al.
Therapeutic Innovation & Regulatory Science (2021) Vol. 56, Iss. 1, pp. 8-14
Open Access | Times Cited: 49
Understanding Use of Real‐World Data and Real‐World Evidence to Support Regulatory Decisions on Medical Product Effectiveness
Nirosha Mahendraratnam, Kerra Mercon, Mira Gill, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 111, Iss. 1, pp. 150-154
Closed Access | Times Cited: 46
Use of Real-Time Continuous Glucose Monitoring Improves Glycemic Control and Other Clinical Outcomes in Type 2 Diabetes Patients Treated with Less Intensive Therapy
Thomas Grace, Jay Salyer
Diabetes Technology & Therapeutics (2021) Vol. 24, Iss. 1, pp. 26-31
Open Access | Times Cited: 43
Real‐world evidence for the long‐term effect of allergen immunotherapy: Current status on database‐derived European studies
Christian Vogelberg, Ludger Klimek, Bernd Brüggenjürgen, et al.
Allergy (2022) Vol. 77, Iss. 12, pp. 3584-3592
Open Access | Times Cited: 33
Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective
Laurent Azoulay
The Oncologist (2022) Vol. 27, Iss. 9, pp. e731-e738
Open Access | Times Cited: 31
Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensus
Yared Santa‐Ana‐Téllez, Bart Lagerwaard, Amos J. de Jong, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 4, pp. 103520-103520
Open Access | Times Cited: 20
Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial
Sophie Dupuis‐Girod, Sophie Rivière, Christian Lavigne, et al.
Journal of Internal Medicine (2023) Vol. 294, Iss. 6, pp. 761-774
Open Access | Times Cited: 20
Current Technology Developments Can Improve the Quality of Research and Level of Evidence for Rehabilitation Interventions: A Narrative Review
Bruno Bonnechère, Annick Timmermans, Sarah Michiels
Sensors (2023) Vol. 23, Iss. 2, pp. 875-875
Open Access | Times Cited: 18
Real‐world evidence to support regulatory submissions: A landscape review and assessment of use cases
Golnoosh Alipour‐Haris, Xinyue Liu, Virginia Acha, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 8
Open Access | Times Cited: 7
Clinical efficacy of adjunctive esketamine anesthesia in electroconvulsive therapy for major depressive disorders: A pragmatic, randomized, controlled trial
Li Ren, Qibin Chen, Jin Gao, et al.
Psychiatry Research (2024) Vol. 335, pp. 115843-115843
Closed Access | Times Cited: 6
Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model
Meng Li, Shengqi Chen, Yunfeng Lai, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 38
Use of Real‐World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019
Sini Marika Eskola, Hubertus G.M. Leufkens, Andrew Bate, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 111, Iss. 1, pp. 310-320
Open Access | Times Cited: 38
Role of Disease Progression Models in Drug Development
Jeffrey S. Barrett, Tim Nicholas, Karim Azer, et al.
Pharmaceutical Research (2022) Vol. 39, Iss. 8, pp. 1803-1815
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top